NY Times — Federal regulators have raised another red flag about the quality of generic drugs, sending a warning letter to a leading maker about manufacturing violations.
| Read at New York Times |
| Read at PharmaLive |
| Read at News Release |
Related posts:
Join hundreds of students and get all book resources for FREE! Subscribe to Pharmacy E-books via RSS or via E-mail
